Nasdaq warns Gelteq (NASDAQ: GELS) after shares stay below $1.00

Rhea-AI Filing Summary

Gelteq Limited received a notice from Nasdaq on March 18, 2026 that its ordinary shares failed to meet the minimum bid price requirement of $1.00 for 30 consecutive business days under Nasdaq Listing Rule 5550(a)(2). The shares remain listed and continue trading under the symbol GELS.

The company has until September 14, 2026 to regain compliance. If its closing bid price is at least $1.00 for at least ten consecutive business days within this period, Nasdaq will confirm compliance. If Gelteq does not regain compliance by that date, it may qualify for an additional 180‑day grace period, potentially including actions such as a reverse stock split.

Positive

• None.

Negative

• Nasdaq minimum bid price deficiency: Gelteq’s ordinary shares traded below the $1.00 minimum bid for 30 consecutive business days, triggering a formal non‑compliance notice and creating a defined risk to its continued Nasdaq listing if compliance is not restored.

Insights

Equity Markets & Listing Standards Analyst

Nasdaq has flagged Gelteq for a sub‑$1 share price, starting a defined cure period.

Gelteq Limited has fallen out of compliance with Nasdaq’s $1.00 minimum bid price rule after trading below this threshold for 30 consecutive business days. The shares remain listed and continue to trade under the GELS ticker, so there is no immediate trading disruption.

The company now has until September 14, 2026 to achieve a closing bid price of at least $1.00 for ten straight business days. If it fails to do so, Nasdaq may grant another 180‑day period if other Capital Market listing standards, including market value of publicly held shares, are met.

The disclosure notes the option to cure via measures such as a reverse stock split during a second compliance period. Subsequent company communications and future periodic filings will clarify whether market performance alone restores compliance or whether corporate actions are implemented.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of March 2026

Commission File Number: 001-42373

Gelteq Limited

(Registrant’s Name)

Level 19

644 Chapel Street

South Yarra VIC, 3141
Australia

(Address of Principal Executive Offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F ☒   Form 40-F ☐

INFORMATION CONTAINED IN THIS FORM 6-K REPORT 

On March 18, 2026, Gelteq Limited (the “Company”) received a letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that the closing bid price per share for its ordinary shares, no par value, (“Ordinary Shares”) was below $1.00 for a period of 30 consecutive business days and that the Company did not meet the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2). The Nasdaq notification letter does not result in the immediate delisting of the Company’s Ordinary Shares, and the shares will continue to trade uninterrupted under the symbol “GELS.”

Pursuant to Nasdaq Listing Rule 5810(c)(3)(A), the Company has a compliance period of one hundred eighty (180) calendar days, or until September 14, 2026 (the “Compliance Period”), to regain compliance with Nasdaq’s minimum bid price requirement. If at any time during the Compliance Period, the closing bid price per share of the Company’s Ordinary Shares is at least $1.00 for a minimum of ten (10) consecutive business days, Nasdaq will provide the Company a written confirmation of compliance and the matter will be closed.

In the event the Company does not regain compliance by September 14, 2026, the Company may be eligible for an additional 180 calendar day grace period. To qualify, the Company will be required to meet the continued listing requirement for market value of publicly held shares and all other initial listing standards for The Nasdaq Capital Market, with the exception of the bid price requirement, and will need to provide written notice of its intention to cure the deficiency during the second compliance period, including by effecting a reverse stock split, if necessary.

1

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	Gelteq Limited
	By:	/s/ Nathan Givoni
	Name:	Nathan Givoni
	Title:	Chief Executive Officer

Date: March 24, 2026

2

FAQ

What Nasdaq notice did Gelteq Limited (GELS) receive in March 2026?

Nasdaq notified Gelteq Limited that its ordinary shares failed the $1.00 minimum bid price requirement after trading below that level for 30 consecutive business days. The notice cites Nasdaq Listing Rule 5550(a)(2) but does not trigger immediate delisting of GELS shares.

Is Gelteq Limited (GELS) being immediately delisted from Nasdaq?

No, Gelteq’s ordinary shares are not being immediately delisted. The shares continue to trade uninterrupted on The Nasdaq Capital Market under the symbol GELS while the company works through a defined compliance period to restore its minimum bid price.

How long does Gelteq Limited have to regain Nasdaq minimum bid price compliance?

Gelteq has until September 14, 2026 to regain compliance with Nasdaq’s $1.00 minimum bid requirement. Achieving a closing bid of at least $1.00 for ten consecutive business days during this period would lead Nasdaq to confirm compliance and close the matter.

Can Gelteq Limited receive additional time beyond September 14, 2026 to meet Nasdaq rules?

Yes. If Gelteq has not regained compliance by September 14, 2026, it may qualify for an additional 180-day grace period. Eligibility requires meeting other Nasdaq Capital Market initial listing standards, including market value of publicly held shares, except for the bid price rule.

What actions might Gelteq Limited take to cure the Nasdaq bid price deficiency?

The disclosure notes Gelteq could indicate an intention to cure the deficiency during a second compliance period, including by effecting a reverse stock split if necessary. Any such action would be aimed at raising the share price to meet Nasdaq’s $1.00 minimum bid requirement.

What specific Nasdaq rules are referenced in Gelteq Limited’s notice?

The notice references Nasdaq Listing Rule 5550(a)(2) for the $1.00 minimum bid price requirement and Rule 5810(c)(3)(A), which provides a 180-day compliance period. Together, these rules define both the deficiency and the timeframe for Gelteq to regain compliance.